Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.51 USD | -5.62% | -15.17% | -43.45% |
Business Summary
Number of employees: 12
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cancer Medicines
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Robert Spiegel
BRD | Director/Board Member | 73 | 18-09-11 |
Samuel Barker
BRD | Director/Board Member | 81 | 14-09-10 |
Kenneth Ferguson
BRD | Director/Board Member | 68 | 22-06-13 |
Karin Walker
BRD | Director/Board Member | 60 | 20-11-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 119,000 | 0 | 0 | 74.05 % |
Stock B | 0 | 264 | 0 | 0 | |
Stock C | 1 | 1,318,257 | 1,224,417 ( 92.88 %) | 0 | |
Stock D | 0 | 335,273 | 0 | 0 |
Company contact information
Cyclacel Pharmaceuticals, Inc.
200 Connell Drive Suite 1500
07922, Berkeley Heights
+908 517 7330
http://www.cyclacel.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.45% | 1.99M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CYCC Stock
- Company Cyclacel Pharmaceuticals, Inc.